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Abstract
Background: Non-tuberculous mycobacteria (NTM) are opportunistic pathogens in immuno-compromised patients.
They are also increasingly recognized as pathogens in immuno-competent individuals. Globally, an increase in NTM
isolation is being reported with a varied geographic prevalence of different species around the world. There is lack
of data on species distribution of these organisms from Pakistan. Treatment options differ according to the species
isolated and its susceptibility profile. Knowledge of local species variation would help targeted therapy. This study
was performed to determine frequencies of different NTM species isolated from various clinical specimens
submitted at a tertiary care hospital laboratory.
Methods: NTM isolated from 25955 clinical specimens over a period of two years (2010 to 2011) were included. All
NTM were identified using conventional tests. Drug susceptibility testing (DST) was performed by broth
microdilution and interpreted according to Clinical and Laboratory Standards Institute’s document M24-A2.
Results: A total of 104 NTM were included in the study. Of these, 76% (54/71) rapidly growing mycobacteria (RGM)
and 57.6% (19/33) slow growing mycobacteria (SGM) could be further identified. Mycobacterium fortuitum (21/54) was
the commonest NTM identified among RGM followed by M. mucogenicum (12/54) and M. smegmatis (11/54). Among
SGM, M. avium complex (MAC) was the most frequent (14/19). Clinical significance could be assessed in a limited
number (52/104) of NTM isolates and MAC appeared to be the commonest significant NTM. Three extra-pulmonary
cases were found to be healthcare associated infections. DST results for RGM showed susceptibility to amikacin (100%),
clarithromycin (100%, except M. fortuitum where it is not reportable), linezolid (90%) and moxifloxacin (75%). Whereas
SGM were susceptible to clarithromycin (100%), linezolid (58.8%) and moxifloxacin (64.7%).
Conclusion: This is the first study reporting NTM species and their clinical significance isolated from clinical specimens
from Pakistan. Isolation of NTM from clinical specimens should prompt to evaluate their clinical significance.
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Background
Non-tuberculous mycobacteria (NTM) also known as
mycobacteria other than tuberculosis (MOTT) are acid fast
bacilli that do not belong to Mycobacterium tuberculosis
complex or Mycobacterium leprae. These mycobacteria are
environmental organisms and are found in natural bodies
of waters, biofilms, soil, water damaged walls, etc. NTM
may also be found in drinking water supplies. Humans
may get infected with NTM from environmental sources
but unlike M. tuberculosis and M. leprae, evidence for
human to human transmission is lacking. NTM are glo-
bally recognized as pathogens especially in immuno-
compromised population including HIV/AIDS (Human
Immunodeficiency Virus/Acquired Immunodeficiency
Syndrome) patients [1,2]. In addition to causing infec-
tions in immuno-compromised patients, this group of
organisms has been reported to be increasingly recog-
nized as pathogens from immuno-competent individ-
uals as well [3,4].
There has been an increase in the rate of isolation of
NTM. A multi-country retrospective study reported a
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diverse and increasing trend of NTM isolation in 14
countries of the world over a period spanning several
years [5]. This study also highlighted geographical
variation in the pattern of NTM isolation across par-
ticipating countries. For example, M. fortuitum was the
commonest species reported from Iran and Turkey
whereas M. avium complex (MAC) predominated from
most of the European countries and Brazil. From
Belgium, Mycobacterium xenopi while M. gordonae was
the most frequently isolated NTM from Czech Repub-
lic. An increase in the number of isolation of NTM
may be explained by a number of reasons including
increase in the number of immuno-compromised
population including HIV/AIDS, introduction of new
technologies to dissect out related NTM species, in-
creasing knowledge and interest in the isolation of all
Mycobacterium species and impact of human activities
on the ecology of NTM [6]. An increasing trend and
geographical variation in NTM species isolation is also
reported from India [7] and Taiwan [8].
Rising number of NTM isolation is of concern as these
are both difficult to diagnose and treat and the treat-
ment also varies according to the NTM species involved,
its susceptibility profile and the disease site [9]. Treat-
ment of these infections usually involves a combination
of drugs with in vitro activity against a particular NTM
isolate. Various methods including agar disk elution, agar
disk diffusion, E-test have been described but broth
microdilution is considered to be the gold standard for
performing drug susceptibility testing (DST) of NTM.
Interpretation criteria are best defined for MAC, M.
kansasii, M. marinum and rapidly growing mycobacteria
(RGM) until more data become available for other NTM
species [10]. A recently published review on drug sus-
ceptibility testing, resistance mechanisms and therapy of
NTM infections further highlights the importance of
recognizing NTM species and performing DST on sig-
nificant clinical isolates [11].
Pakistan is a high burden country for tuberculosis [12]
and patients with chronic pneumonia, meningitis,
lymphadenitis, pyrexia of unknown origin, chronic non-
healing ulcers/wounds and other chronic infections are
evaluated for tuberculosis by performing microbiological
cultures of various clinical specimens. Besides isolation
of M. tuberculosis, NTM are also isolated from these
specimens. Most of the clinical microbiology laboratories
in Pakistan differentiate Mycobacterium species into M.
tuberculosis and non-tuberculous mycobacteria and do
not attempt to identify NTM to species level. NTM iso-
lated from clinical specimens are reported without fur-
ther identification. From Pakistan, information is lacking
regarding NTM species isolated from clinical specimens.
Therefore, there is a need to identify NTM to species
level that would help targeted treatment.
Methods
Bacterial strains
NTM were prospectively collected from Clinical Labora-
tory, Aga Khan University Hospital (AKUH), Karachi,
Pakistan, from 2010 to 2011. During the study period, 104
NTM were isolated. Strains were saved at −80°C and re-
vived when required. The hospital and its clinical labora-
tory are accredited by the Joint Commission International
Accreditation (JCIA).
Assessment of the clinical significance of an NTM iso-
late is vital for establishing its role in causing patient’s
symptoms. Clinical information is routinely collected at
AKUH Clinical Microbiology Laboratory as good clinical
practice to serve this purpose. This included presenting
symptoms, occupation, co-morbids (e.g. malignancy,
HIV infection), smoking, previous tuberculosis or tuber-
culosis treatment history, chronic obstructive pulmonary
disease, cystic fibrosis, immunosuppression (HIV, malig-
nancy, chemotherapy, steroid intake), surgical procedure
(as a risk factor for extra-pulmonary NTM infections)
and chest X-ray and/or CT scan findings. This informa-
tion has been used and presented in this study anonym-
ously. Significance assessment of NTM isolation was
carried out in cases where clinical information was avail-
able. For extra-pulmonary NTM isolates, diagnosis was
assessed on patient history and by isolation of NTM
from aspirated pus, tissue biopsies or sterile body fluids.
Diagnosis of pulmonary NTM disease was made by cri-
teria (where available) published by American Thoracic
Society/Infectious Diseases Society of America which
combines clinical and microbiological criteria: 1. Clinical
symptoms & appropriate exclusion of other diseases,
and 2. Microbiological (positive culture from at least
two sputum samples, or positive culture from one bron-
chial wash or lavage) [9].
Cultures were performed using Lowenstein Jensen
(LJ), Mycobacterium Growth Indicator Tube (MGIT)
and Middlebrook 7H10 agar for all the specimens by
standard microbiological procedures [13].
Identification of NTM
Colonies growing on solid media were confirmed as AFB
by performing Kinyoun stain. Growth rate (as determined
by subculturing the organism onto Middlebrook 7H10
agar after growing a well isolated colony in Middlebrook
7H9 broth with Tween-80) and colony pigmentation were
assessed. Para-nitro benzoic acid (PNB) sensitive and
thiophene-2-carboxylic acid hydrazide (T2H) resistant
strains (M. tuberculosis ssp. bovis is T2H sensitive) were
identified as M. tuberculosis complex and excluded from
the study. NTM were further identified by following con-
ventional tests: rate of growth, pigment production,
arylsulfatase, heat-stable catalase, growth on MacConkey
agar without crystal violet, iron uptake, nitrate reduction,
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tween-80 hydrolysis, tellurite reduction and urease pro-
duction [13]. American Type Culture Collection (ATCC)
strains (M. fortuitum ATCC6841, M. avium ATCC 25291,
M. tuberculosis ATCC 15177, M. kansasii TCC12478, M.
phlei ATCC11758) and/or selected strains received from
College of American Pathologists’ survey were included as
positive and negative controls (if ATCC strains were not
available) for all the tests performed for the identification
of NTM.
Susceptibility testing
Broth microdilution was used to perform drug susceptibil-
ities using 96 well sensititre plates (TREK Diagnostic Sys-
tems Ltd, UK) as per manufacturer’s recommendations.
Susceptibility data thus obtained was interpreted according
to the Clinical and Laboratory Standards Institute’s criteria
(Susceptibility testing of Mycobacteria, Nocardia and other
aerobic Actinomycetes: Approved standard—second edi-
tion. CLSI document M24-A2. 2011) [10].
Results
A total of 104 clinical NTM isolates were included in the
study. Of these, 92 NTM were isolated from pulmonary
specimens (sputum, tracheal aspirate and bronchoalveolar
lavage fluid) and 12 from extrapulmonary specimens (pus,
tissue biopsies, synovial fluid, pleural fluid) (Table 1). Sev-
enty one (71/104, 68%) NTM were rapidly growing myco-
bacteria (RGM) and 33 (33/104, 32%) were slow growing
mycobacteria (SGM). Among RGM, 54/71 (76%) and 19/
33 (57.6%) SGM could be further identified. Most of the
RGM were M. fortuitum (21/54, 39%) followed by M.
mucogenicum (12/54, 22%) and M. smegmatis (11/54,
20%). Among SGM, most common species was found to
be M. avium (14/19, 73.7%). A map of Pakistan showing
geographical location of various NTM isolated in our
study is shown in Figure 1.
Clinical information was available for 50% of the isolates
(52 NTM from 42 patients) to assess significance of NTM
isolated. Table 2 provides details of pulmonary and
extrapulmonary clinically significant NTM isolates. The
reason for including some of the patients with only one
sputum culture positive for NTM was based on a strong
clinical suspicion of NTM as the cause of patient’s symp-
toms and that most of these patients had AFB smear-
positive from the sample (2nd sputum specimen could not
be collected). Therefore, the diagnosis in these cases is not
certain, but a potential one. Of the pulmonary isolates,
MAC was found to be significant in 4 cases. M. fortuitum,
M. mucogenicum and M. smegmatis were significant in
one case each. For 5 cases, NTM could not be identified
beyond SGM. For extra-pulmonary significant isolates,
one case each was caused by M. mucogenicum, M.
chelonae-abscessus group and M. fortuitum. All three of
these cases appeared to be healthcare associated infec-
tions. MAC was isolated from 2 significant extra-
pulmonary cases.
Table 3 describes drug susceptibility results for NTM.
All RGM were found to be susceptible to amikacin and all
M. chelonae-abscessus and unidentified RGM were sus-
ceptible to clarithromycin. Most of the RGM were also
susceptible to linezolid (18/20, 90%) and moxifloxacin (15/
20, 75%). Susceptibility to doxycycline and imipenem was
noted in 25% and 20% of RGM isolates respectively.
Among 20 RGM isolates 9 (45%) were cotrimoxazole sus-
ceptible. All SGM including MAC isolates were suscep-
tible to clarithromycin. Whereas 4/6 (66.7%) MAC isolates
were susceptible to linezolid and only one was susceptible
to moxifloxacin. All M. kansasii isolates showed suscepti-
bility to moxifloxacin.
Discussion
Non-tuberculous Mycobacteria have gained much clinical
significance in the last couple of decades not only in
immuno-compromised but also in immuno-competent
patients. Their ubiquitous distribution in nature and man-
made ecologies put them at an advantage of having their
hosts close to their ecological niches. NTM cause a wide
variety of infections. Two broad categories include pul-
monary and extra-pulmonary NTM infections. Therapy of
these infections depends on the NTM species isolated, site
of infection and its drug susceptibility profile. Current
guidelines recommend speciation of all clinically signifi-
cant NTM isolates [9]. Published literature describes geo-
graphical variation in NTM species distribution. Present
study is the first from Pakistan describing identification of
NTM species and their clinical significance from clinical
specimens submitted to a tertiary care hospital.
Table 1 Distribution of non-tuberculous mycobacteria
(NTM) from clinical specimens
NTM
identified
Pulmonary
isolates
Extra-pulmonary
isolates
Total
RGM
M. fortuitum 16 5 21
M. chelonae-abscessus 6 0 6
M. mucogenicum 9 3 12
M. smegmatis 11 0 11
M. vaccae 4 0 4
Unidentified 17 0 17
SGM
M. avium complex 11 3 14
M. kansasii 4 0 4
M. flavescens 1 0 1
Unidentified 13 1 14
Total 92 12 104
RGM = rapidly growing Mycobacteria; SGM = slowly growing mycobacteria.
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A total of 104 NTM isolates were included in this
study. Among these, 68% (71/104) were RGM and 32%
(33/104) were SGM. This is in contrast to an Indian
study where 87% of the isolates were reported to be
RGM over a period of 6 years [7]. A study from Taiwan
reported 41.4% of NTM as RGM isolated from 1997–
2003 [8]. In this Taiwanese study 39% of the NTM were
Mycobacterium avium complex (MAC). A study from
Karachi, Pakistan, described M. xenopi as the most
common while M. fortuitum as relatively rare NTM
species among isolates collected from four laboratories
in Karachi [14]. These results are in contrast with the
present study and need further studies to confirm the
findings reported.
In our study, 70% of the NTM could be identified (54/71
from RGM and 19/33 from SGM). M. fortuitum group (21/
71, 29.6%) and MAC (14/33, 42.4%) were the most com-
mon RGM and SGM species isolated respectively in our
study. From India, 46% and 41% of the NTM were M.
chelonae and M. fortuitum respectively among all the
species included in the study [7]. A multi-country study in-
volving 14 countries [5], reported M. fortuitum as the
commonest species from Iran and Turkey and MAC as
most frequent isolate from European countries and Brazil.
Figure 1 Map of Pakistan showing geographical location of various NTM isolated. Pie charts represnet spectrum of NTM isolated: bottom
left (NTM isolated in Karachi); top left (NTM isolated in Peshawar); right (NTM isolated in Lahore). Name of cities are given in bold in each box,
numbers in brackets represent number of each NTM isolated in that city. MF, M. fortuitum; M. mucogenicum; MS, M. smegmatis; MCA, M. chelonae-
abscessus group; MV, M. vaccae; MAC, M. avium complex; MK, M. kansasii; MFl, M. flavescens; Uid, unidentified NTM.
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Belgium had the highest rate for M. xenopi followed by
M. gordonae. Czech Republic was reported to have M.
gordonae and M. kansasii as the most frequent NTM spe-
cies isolated. These findings highlight local and regional
differences in NTM species distribution.
Association of NTM isolate and clinical presentation is
difficult particularly for respiratory isolates owing to the
ubiquitous nature of these organisms. Multiple factors
increase the probability of clinical significance of NTM:
“recovery from multiple specimens or sites, recovery of
the organism in large quantities (AFB smear-positive spec-
imens) or recovery of an NTM isolate from a normally
sterile site” [9]. A total of 27 isolates from 17 patients were
found to be clinically significant. Table 2 describes distri-
bution of NTM isolates according to specimen type in
cases where clinical information was available. This could
be performed for a proportion of cases because clinical de-
tails were available for a limited number of patients. Find-
ing of MAC as the commonest species associated with
clinical disease (4 pulmonary and 2 extra-pulmonary
cases) followed by RGM is in accordance with a study
from Taiwan where most cases were caused by MAC and
RGM [8].
Healthcare associated NTM infections are well docu-
mented in the literature [15,16]. We were able to assess 3
such extra-pulmonary healthcare associated NTM infec-
tions. Medical instruments can easily become contami-
nated with NTM if these are washed with tap water
containing NTM and/or failure to use mycobactericidal
disinfectants [17]. Similarly, fluids used during surgical
procedures or for irrigation of surgical wounds can be-
come contaminated with NTM if adequate sterile prac-
tices are not adhered to, resulting in non-healing surgical
wounds.
Apart from causing healthcare associated infections,
NTM may also contaminate specimens during collection
(e.g. specimen contamination by NTM contained in tap
water used to rinse mouth before sputum collection) [18].
Similarly, laboratories may be reporting an increased num-
ber of NTM because of contamination of reagents used in
processing of specimens [19]. Therefore, isolation of NTM
from clinical specimens should be evaluated carefully in
the light of clinical information to assess their significance.
Proper management of patients with a particular NTM
infection depends on drug susceptibility testing performed
by standard methodology. We performed DST of NTM
Table 2 Clinically significant NTM (pulmonary and
extra-pulmonary) isolates and their distribution
among patients according to specimen type
Specimen/number
of specimens
Specimen
AFB smear
NTM isolated
Pulmonary isolates
Sputum/2 Numerous AFB M. fortuitum
Sputum/1 Moderate AFB M. mucogenicum
Sputum/2 Few AFB M. smegmatis
Sputum/4 Numerous AFB MAC
Sputum/1 Numerous AFB SGM
Sputum/1 Numerous AFB SGM
Sputum/1 Numerous AFB MAC
Sputum/1 Negative SGM
BAL/1 Numerous AFB SGM
Sputum/1 Few AFB SGM
Sputum/2 Few AFB MAC
Sputum/1 Negative MAC
Extra-pulmonary isolates
Pus/2 Negative M. mucogenicum
Pus/2 Negative M. chelonae/abscessus
Synovial fluid, synovium &
granulation tissue/3
Negative M. fortuitum
Lymph node pus/1 Numerous AFB MAC
Pus/1 Negative MAC
NTM, non-tuberculous mycobacteria; MAC, Mycobacterium avium complex; AFB,
acid fast bacilli; BAL, bronchoalveolar lavage; SGM, slow growing mycobacteria.
Table 3 NTM species and antibiotic susceptibilities as determined by broth microdilution
NTM spp. n Number and proportion (%) of susceptible strains to given antibiotics
AK CIP CLA DOX IPM LZD MOX SXT
M. fortiutum 6 6 4 - 1 1 5 4 3
M. cheloane-abscessus 6 6 4 6 1 3 5 6 4
Unidentified RGM 8 8 1 8 3 0 8 5 2
Total RGM 20 20 (100) 9 (45) 14 (100) 5 (25) 4 (20) 18 (90) 15 (75) 9 (45)
MAC 6 - - 6 - - 4 1 -
M. kansasii 4 - 1 4 - - 3 4 2
Unidentified SGM 7 - - 7 - - 3 6 -
Total SGM 17 - - 17 (100) - - 10 (58.8) 11 (64.7) -
Lines labeled with Total RGM and Total SGM represent total number of RGM or SGM tested for each antibiotic listed.
NTM, non-tuberculous mycobacteria; MAC, Mycobacterium avium complex; n = number of isolates tested; AK, amikacin; CIP, ciprofloxacin; CLA, clarithromycin; DOX,
doxycycline; IPM, imipenem; LZD, linezolid; MOX, moxifloxacin; SXT, cotrimoxazole.
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isolates by broth microdilution which is a reference
method as recommended by CLSI [10]. Because of lim-
ited information on pharmacokinetic data to inform de-
cisions regarding therapeutic MICs, discrepancies exist
between in vitro DST and in vivo treatment outcomes
[20]. American Thoracic Society/Infectious Diseases So-
ciety of America (ATS/IDSA) guidelines generally rec-
ommend a combination of agents based on in vitro DST
results. Amikacin was found to inhibit all our RGM iso-
lates that were tested and similarly all RGM were sus-
ceptible to clarithromycin (except for M. fortuitum
group where it is not recommended because of the
presence of an inducible macrolide resistance ‘erm’
gene). Linezolid also seems to be a good option for
RGM treatment. Quinolone susceptibility was found to
be variable with 45% and 75% isolates susceptible to
ciprofloxacin and moxifloxacin respectively suggesting
that these agents may be used in treatment regimens.
Imipenem results are not encouraging with only 20%
RGM found susceptible. Therefore in our setting, treat-
ment options for M. fortuitum infections would be a
combination of two agents with in vitro activity and that
may include amikacin with a quinolone, linezolid or
cotrimoxazole or two oral agents if amikacin cannot be
tolerated. Looking at the DST results, clarithromycin
either with amikacin or linezolid appears to be an op-
tion for treating M. chelonae-abscessus infections. For
MAC, all isolates were susceptible to clarithromycin
and most (4/6, 66.7%) were susceptible to linezolid.
Only one isolate was susceptible to moxifloxacin.
Thus, clarithromycin which is the first line agent for
the treatment of MAC infection in a multidrug regimen
(including ethambutol, rifamycin and/or amikacin/strepto-
mycin depending on the disease severity) appears a viable
option. Though, rifampin, isoniazid, ethambutol, ethion-
amide, streptomycin and clarithromycin are inhibitory for
M. kansasii isolates, but susceptibility breakpoints are not
established for all of these drugs. Routine testing of rifampin
and clarithromycin only is recommended for M. kansasii
isolates. All our M. kansasii isolates were susceptible to
clarithromycin and moxifloxacin and may be utilized for
treatment in a multidrug regimen.
This study has certain limitations. Currently, mo-
lecular identification is used to identify related/newer
NTM species. We could not perform molecular identi-
fication for our NTM isolates to show concordance.
However, in resource limited settings where these
newer technologies are not widely used either because
of cost or lack of expertise, conventional test based
NTM identification should be undertaken in an at-
tempt to identify clinically significant isolates. Another
limitation of this study is unavailability of clinical de-
tails for all the cases which limited our ability to assess
their clinical significance.
Conclusions
This is the first study reporting NTM species and their
clinical significance isolated from clinical specimens
from Pakistan. This study provides a baseline for future
studies to compare NTM isolation and their antimicro-
bial susceptibilities.
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